Lyell Immunopharma's dual-target cancer therapy eyes $3B lymphoma market
Lyell Immunopharma's dual-target cancer therapy eyes $3B lymphoma market
Lyell Immunopharma's dual-target cancer therapy eyes $3B lymphoma market
Lyell Immunopharma is advancing new treatments for aggressive cancers using next-generation cell therapies. The company’s lead programme, ronde-cel, targets a $3 billion market for large B-cell lymphoma. CEO Lynn Seely will discuss these developments at an upcoming investor conference.
The biotech firm specialises in CAR T-cell therapies for both blood cancers and solid tumours. Its flagship therapy, ronde-cel, is a dual-targeted treatment for large B-cell lymphoma, focusing on CD19 and CD20 markers. If successful, it could set a new benchmark in a market currently valued at $3 billion.
Beyond blood cancers, Lyell is also working on a novel CAR T-cell therapy for metastatic colorectal cancer. This second programme aims to address a major unmet need in a large patient population. On May 19, 2026, CEO Lynn Seely will take part in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The session is scheduled for 11:00 AM EDT, offering investors insights into the company’s progress and future plans.
Lyell’s therapies could reshape treatment options for patients with hard-to-treat cancers. Ronde-cel’s potential in large B-cell lymphoma and the colorectal cancer programme highlight the company’s push into high-value markets. Seely’s upcoming discussion may provide further clarity on development timelines and commercial strategies.